跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
gene therapy (retinitis pigmentosa)
首页
药物
gene therapy (retinitis pigmentosa)
gene therapy (retinitis pigmentosa)
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
GENE THERAPY FOR RETINITIS PIGMENTOSA
申请人: GENZYME CORP
优先权: 2014
CN
EP
US
WO
9 件公开
RPGR GENE THERAPY FOR RETINITIS PIGMENTOSA
申请人: MASSACHUSETTS EYE & EAR INFIRMARY
优先权: 2014
CN
EP
US
WO
9 件公开
GENE AUGMENTATION THERAPIES FOR INHERITED RETINAL DEGENERATION CAUSED BY MUTATIONS IN THE PRPF31 GENE
申请人: MASSACHUSETTS EYE & EAR INFIRMARY
优先权: 2015
EP
US
WO
5 件公开
GENE THERAPY FOR THE TREATMENT OF CNGB1-LINKED RETINITIS PIGMENTOSA
申请人: MICHALAKIS STYLIANOS
优先权: 2017
EP
US
WO
5 件公开
Compositions and methods for ameliorating myosin VIIa defects
申请人: UNIV CALIFORNIA
优先权: 2008
US
3 件公开
GENE AUGMENTATION THERAPY FOR USHER SYNDROME 1B
申请人: THE REGENTS OF UNIV OF CALIFORNIA
优先权: 2023
EP
WO
2 件公开
Retinal protective factor 2 (RPF2) protein delivered by adeno-associated virus expression
申请人: UNIV FLORIDA
优先权: 2019
US
2 件公开
Method used for inducing differentiation of human multipotential stem cells into retinal progenitor cells
申请人: UNIV FUDAN
优先权: 2012
CN
Codon optimized nucleic acid encoding a retinitis pigmentosa gtpase regulator (RPGR)
申请人: YE GUO-JIE
优先权: 2015
US
Gene therapy vector for treating retinitis pigmentosa disease
申请人: SHANGHAI INNOSTELLAR BIOTHERAPEUTICS CO LTD
优先权: 2018
US
第 1 / 2 页
上一页
下一页
药物
反馈